NetraMark to Attend Canaccord Genuity’s 45th Annual Growth Conference
TORONTO, July 31, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)...
Year: 2025
STRATA Skin Sciences to Report Second Quarter 2025 Financial Results on August 13, 2025 and Provide Corporate Update
HORSHAM, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical...
Profusa Secures Lumee™ Oxygen Platform Distributor in Spain
BERKELEY, Calif, July 31, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital...
Vericel Reports Second Quarter 2025 Financial Results
Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased...
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapiesROCKVILLE, Md., July 31,...
Dr. Michelle LeRoux Williams Earns Washington Business Journal’s Medical Device Innovator Award
GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting...
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025
SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7
DUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines...
Nautilus Biotechnology Reports Second Quarter 2025 Financial Results
SEATTLE, July 31, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome...
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
BASKING RIDGE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Inka Health Selected by OneMedNet to Lead AI-Driven Oncology Project Using Real-World Data for External Control Arms
Reduce development timelines and costs, while improving access to life-saving treatmentsVANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- Onco-Innovations...
VedTechBio Unveils Next-Gen Drug Discovery AI; Partners with AlphaMeld in Multi-Therapy Collaboration
BENGALURU, India, July 31, 2025 (GLOBE NEWSWIRE) -- VedTechBio Research Pvt. Ltd., a pioneer in AI-driven drug discovery, today announced...
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights
Akebia to Host Conference Call on August 7, 2025, at 8:00 a.m. EDTCAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) --...
LifeMD Names COO and Promotes Two Executives
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual healthcare services, today...
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
THE WOODLANDS, Texas, July 31, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Nasdaq’s listing qualifications...
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase...
Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid Tumors...
BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study
PHILADELPHIA and VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT)...
Kura Oncology to Report Second Quarter 2025 Financial Results
SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...